A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
Public ClinicalTrials.gov record NCT02584660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.
Study identification
- NCT ID
- NCT02584660
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 114 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2015 (Actual)
- Primary completion
- Mar 22, 2017 (Actual)
- Completion
- Mar 22, 2017 (Actual)
- Last update posted
- Jun 1, 2018
2015 – 2017
United States locations
- U.S. sites
- 50
- U.S. states
- 22
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Montgomery | Alabama | — | — |
| Not listed | Chandler | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Sylmar | California | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Pensacola | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Davenport | Iowa | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Jackson | Michigan | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Atlantic City | New Jersey | — | — |
| Not listed | Camden | New Jersey | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Stony Brook | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Zanesville | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Bethlehem | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Bellingham | Washington | — | — |
| Not listed | Everett | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02584660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2018 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02584660 live on ClinicalTrials.gov.